These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19652644)

  • 21. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
    Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Liu Q; Mier JW; Panka DJ
    Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Hamed HA; Tang Y; Cruickshanks N; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Autophagy; 2011 Oct; 7(10):1261-2. PubMed ID: 21814046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
    Vistica DT; Hollingshead M; Borgel SD; Kenney S; Stockwin LH; Raffeld M; Schrump DS; Burkett S; Stone G; Butcher DO; Shoemaker RH
    J Pediatr Hematol Oncol; 2009 Aug; 31(8):561-70. PubMed ID: 19636271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
    Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
    Zhang K; Waxman DJ
    Mol Cancer Ther; 2013 May; 12(5):787-98. PubMed ID: 23635653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
    Huang FK; Shi Z
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):808-12. PubMed ID: 21223684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
    Lemasson B; Christen T; Tizon X; Farion R; Fondraz N; Provent P; Segebarth C; Barbier EL; Genne P; Duchamp O; Remy C
    NMR Biomed; 2011 Jun; 24(5):473-82. PubMed ID: 21674650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
    Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.
    Righi M; Locatelli SL; Carlo-Stella C; Presta M; Giacomini A
    Sci Rep; 2018 Nov; 8(1):17520. PubMed ID: 30504794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
    Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F
    PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.